INS and metabolic dysfunction-associated steatotic liver disease: Previous investigations have shown a decreased capacity of insulin to inhibit endogenous glucose synthesis in patients with NAFLD, indicating hepatic IR [28,29,30], as well as a 45–50% decrease in whole-body glucose disposal [28,29].